310P Neoadjuvant chemotherapy in ER+/HER2-negative or HER2-low early breast cancer: pCR, compliance, and predictors in a single-center cohort
ESMO Open · 2026-05 · 11 · 107261
DOI: 10.1016/j.esmoop.2026.107261 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESMO Open, 2026-05. Verfasst von N.S. Al Gazlan und 10 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Gazlan, N. A., Alwohaibi, A., Almazyad, A., Rudainee, M., Alharbi, M., AlTamimi, A., Faqihi, F., Aldawoud, M., Alturki, A., Bakhribah, H., & Altwairgi, A. (2026). 310P Neoadjuvant chemotherapy in ER+/HER2-negative or HER2-low early breast cancer: pCR, compliance, and predictors in a single-center cohort. ESMO Open, 11, 107261. https://doi.org/10.1016/j.esmoop.2026.107261
Vancouver
Gazlan NA, Alwohaibi A, Almazyad A, Rudainee M, Alharbi M, AlTamimi A, et al. 310P Neoadjuvant chemotherapy in ER+/HER2-negative or HER2-low early breast cancer: pCR, compliance, and predictors in a single-center cohort. ESMO Open. 2026;11:107261. doi:10.1016/j.esmoop.2026.107261
BibTeX
@article{Gazlan2026,
author = {Gazlan, N.S. Al and Alwohaibi, A. and Almazyad, A. and Rudainee, M. and Alharbi, M. and AlTamimi, A. and Faqihi, F. and Aldawoud, M.F. and Alturki, A. and Bakhribah, H.M.H.M. and Altwairgi, A.K.},
title = {310P Neoadjuvant chemotherapy in ER+/HER2-negative or HER2-low early breast cancer: pCR, compliance, and predictors in a single-center cohort},
journal = {ESMO Open},
year = {2026},
volume = {11},
pages = {107261},
doi = {10.1016/j.esmoop.2026.107261}
}
EUVIMED